Measurement of CD16⁺CD56⁺ NK cells, lymphocyte count, and clinical features during treatment with alemtuzumab. Treatment of CNKL with alemtuzumab effectively improved livedo reticularis (A) and cutaneous ulcers (B), and this correlated with a decrease in CD16⁺CD56⁺ NK cells (C) and reconstitution of the total lymphocytes (D). ALC indicates absolute lymphocyte count.